Astrazeneca Pharma India Ltd Share Price

Pharmaceuticals

NSE: ASTRAZEN Small Cap ISIN: INE203A01020

As on 18 March 2025 at 23:29 IST

₹7,908.65

+ 196.25

(2.54%)

Sell Buy

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma Ltd is a global, science-led biopharmaceutical company focusing on discovering, developing, and commercialising prescription medicines. It falls under the pharmaceutical sector, specifically within the biopharmaceutical sub-sector. The company was founded in 1999. The headquarters of AstraZeneca Pharma Ltd is located in Bengaluru, Karnataka. The company is known for its innovative medicines, which include treatments for cancer, cardiovascular diseases, diabetes, respiratory diseases, and rare diseases. Some of its well-known products include Tagrisso, Symbicort, and Farxiga. The company operates primarily in four therapy areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory. +

Over 1 Month

10.06%

Over 6 Months

15.85%

Over 1 Year

51.31%

Over 3 Years

188%

Astrazeneca Pharma India Ltd Summary

Close ₹7,908.65

Open ₹7,784.15

High ₹8,020

Low ₹7,712.40

Volume 32,252

Net Turnover (in Cr) ₹25.38

52Wk High ₹8,139

52Wk Low ₹4,800.15

52Wk High / Low

4,800.15

8,139

Astrazeneca Pharma India Ltd Fundamentals

Key Financial Data

Market Cap (in Cr) ₹19,771.63

EPS (TTM) 67.05

Book Value (BV) 271.74

Div. Yield 0.30 %

P/E (TTM) 204.40

Price/Book Value 29.18

Delivery % 31.61 %

Face Value 2

Key Ratios

PE Ratio 82.36

PB Ratio 18.68

EV to Sales 9.88

PEG Ratio 1.31

ROA 22.35

ROE 24.84

Debt-Equity 0.01

Net Profit Margin 12.47

Operating Profit Margin 18.19

Astrazeneca Pharma India Ltd Financials

Profit and Loss

Consolidated

Standalone

Yearly

Quarterly

No data available

Balance Sheet

No data available

Cash Flow

No data available

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	1,330.33	1,029.07	820.36	826.40	844.80
Total Expenses	1,127.22	854.74	737.32	699.31	730.83
Profit Before Tax	219.54	134.10	83.04	127.09	113.97
Profit After Tax	161.51	99.29	61.60	93.30	72.21
Operating Profit after Depreciation	204.31	174.96	83.99	128.18	115.11

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	66.68	68.86	74.49	80.96	71.53
Total Non Current Assets	145.32	149.40	150.89	155.95	164.04
Total Current Assets	932.71	835.47	705.67	618.76	542.32
TOTAL ASSETS	1,078.03	984.87	856.56	774.71	706.36
Total Shareholder's Fund	711.92	588.69	511.39	456.17	364.44

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	27.87	58.29	100.80	104.78	87.42
Net Cash used in Investing Activities	21.74	18.11	4.74	173.03	-170.80
Net Cash used in Financing Activities	-44.38	-24.48	-9.46	-8.97	-6.36

No data available

Particulars (in ₹ Cr.)	2024-12	2024-09	2024-06	2024-03	2023-12
Total Revenue	440.29	408	387.52	383.20	305.79
Total Expenses	363.30	355.46	349.45	333.81	290.74
Profit Before Tax	42.02	51.03	-15.16	54.36	20.40
Profit After Tax	30.85	38.43	-11.79	39.48	15.80
Operating Profit after Depreciation	84.97	60.69	46.42	58.05	24.71

Astrazeneca Pharma India Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 7,610.70

S2 7,509

S3 7,381

Pivot 7,738.70

R1 7,840.40

R2 7,968.40

R3 8,070.10

Moving Average

20 SMA 7,213.36

50 SMA 7,189.32

100 SMA 7,024.58

200 SMA 6,929.70

Astrazeneca Pharma India Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

Astrazeneca Pharma India Ltd

₹24/Share

Announcement Date 05 Jul 2024

Record Date 05 Jul 2024

Div Yield 1200%

AGM Date: 08 Aug 2022

AGM 08/08/2022 Pursuant to Regulation 34(1) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the Annual Report of the Company for the financial year ended March 31, 2022 along with the Notice of the Annual General Meeting of the Company scheduled to be held on Monday, August 8, 2022 at 3.00 p.m. (IST) through Video Conferencing (VC)/ Other Audio Visual Means (OAVM). The Annual Report is being sent to the members who have registered their email ID with the Company/ Depositories. The Annual Report is also available on the website of the Company at www.astrazeneca.com/india. (As Per BSE Announcement Dated on 15/07/2022) Newspaper Advertisements of Intimation of 43rd Annual General Meeting & e-voting (As Per BSE Announcement Dated on 20.07.2022) Pursuant to Clause 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we furnish the attached details regarding voting results of 43rd Annual General Meeting of the Company held on Monday, August 8, 2022 at 3.00 pm through Video Conferencing/ Other Audio Visual Means along with the scrutinizer's report. AstraZeneca Pharma India Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. We would like to inform you that the attached business were transacted at the 43rd Annual General Meeting (AGM) of the Company held on August 8, 2022 at 3.00 P.M. through Video Conferencing/Other Audio Visual Means. Kindly note that voting results will be announced upon the receipt of Scrutinizer's Report and will be submitted as per Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. (As Per BSE Announcement Dated on 09.08.2022) In continuation of our earlier announcement dated December 30, 2021, we wish to inform you that at the Company's Annual General Meeting held on August 8, 2022, the Shareholders have approved the appointment of Ms. Shilpa Shridhar Divekar, as an Independent Director for a term of 5 years with effect from December 29, 2021 till December 28, 2026. The requisite details of the appointment pursuant to Regulation 30 of the Listing Regulations read with SEBI Circular dated September 9, 2015, are given as Annexure A. (As Per BSE Announcement dated on 10.08.2022)

AGM Date: 14 Aug 2023

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed the Notice of the 44th Annual General Meeting of the Company scheduled to be held on Monday, August 14, 2023 at 3.00 p.m. (IST) through Video Conferencing (VC)/ Other Audio Visual Means (OAVM). The Notice is being sent to the Members of the Company through electronic mode. The said Notice and the Annual Report for the Financial Year ended March 31, 2023 is available on the website of the Company at www.astrazeneca.com/india. Summary of Proceedings of 44th Annual General Meeting. (As Per BSE Announcement Dated on 15/08/2023) Voting Results and Scrutinizer''s Report of 44th Annual General Meeting of the Company held on August 14, 2023. (As Per BSE Announcement dated on 17.08.2023) In furtherance to your email dated April 6, 2024 and the enclosed summary of proceedings of 44th Annual General Meeting held on August 14, 2023, we wish to inform that that the 44th Annual General Meeting commenced at 3:00 PM and concluded at 4:45 PM (IST). (As Per BSE Announcement Dated on 08.04.2024)

AGM Date: 08 Aug 2024

AGM 08/08/2024 Please find the enclosed document of the Company in relation to the summary of proceedings of the 45th Annual General Meeting of the Company. (As per BSE Announcement Dated on 08/08/2024) Please find the enclosed Voting Results and the Scrutinizer''s Report of 45th Annual General Meeting of the Company held on August 8, 2024. (As Per BSE Announcement Dated on: 09/08/2024)

Astrazeneca Pharma India Ltd Peer Comparison

Company	Price	Market Cap (in Cr)
Sun Pharmaceuticals Industries Ltd	₹1,748.60	₹4,19,547.71
Divis Laboratories Ltd	₹5,777.90	₹1,53,385.09
Cipla Ltd	₹1,508.70	₹1,21,844.87
Torrent Pharmaceuticals Ltd	₹3,135.60	₹1,06,118.19
Dr Reddys Laboratories Ltd	₹1,164.70	₹97,189.02

Astrazeneca Pharma India Ltd Top Mutal Funds Invested

Fund Name	AUM
Nippon India Small Cap Fund	0.87%
ICICI Pru Smallcap Fund	1.20%
ICICI Pru P.H.D Fund	1.71%
ICICI Pru Innovation Fund	0.79%
Bandhan Innovation Fund	3.55%

Astrazeneca Pharma India Ltd News

Astrazeneca Pharma gains after receiving approval from CDSO to import Durvalumab solution.

Astrazeneca Pharma India added 2.08% to Rs 6846.10 after the company has received permission from the Central Drugs Standard Control Organisation (CDSCO) to import for sale and distribution of Durvalumab solution.

03 Mar 2025, 02:43 pm

Astrazeneca Pharma gains after Q3 PAT soars to Rs 55 cr

Astrazeneca Pharma India advanced 1.21% to Rs 7557.05 after the company's standalone net profit surged to Rs 54.68 crore in Q3 FY25 as compared with Rs 15.80 crore in Q3 FY24.

12 Feb 2025, 11:47 am

Astrazeneca Pharma India to hold board meeting

On 11 February 2025

21 Jan 2025, 10:45 am

Volumes spurt at Astrazeneca Pharma India Ltd counter

Astrazeneca Pharma India Ltd registered volume of 3.94 lakh shares by 14:14 IST on NSE, a 79.61 fold spurt over two-week average daily volume of 4955 shares

30 Dec 2024, 02:30 pm

AstraZeneca gets CDSCO nod to import cancer drug, Lynparza

AstraZeneca Pharma India said that it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute Olaparib film-coated tablets 100 mg & 150 mg (Lynparza) for an additional indication in India.

26 Nov 2024, 02:49 pm

Astrazeneca Pharma India Ltd Stock Analysis

Annual revenue for Astrazeneca Pharma India Ltd increased by 29.27% to ₹1,330.33 crore in FY 2024 from ₹1,029.07 crore in FY 2023.
Annual Net Profit for Astrazeneca Pharma India Ltd increased by 62.66% to ₹161.51 crore in FY 2024 from ₹99.29 crore in FY 2023.
Promoter Shareholding in Astrazeneca Pharma India Ltd remains unchanged by 0.00% in the most recent quarter, from 75% in September 2024 to 75% in December 2024.
Astrazeneca Pharma India Ltd delivered a 1-year return of 51.31% compared to the Nifty 50, which provided a return of 2.05% as of the last trading session.
Astrazeneca Pharma India Ltd share price moved up by 2.54% from its previous close of INR ₹7,712.40. The latest Astrazeneca Pharma India Ltd share price is INR ₹7,908.65.
Astrazeneca Pharma India Ltd share price today has been at a low of 7,712.40 and a high of 8,020. Over the past 52 weeks, the Astrazeneca Pharma India Ltd share price has seen a low of 4,800.15 and a high of 8,139.

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma Ltd is a global, science-led biopharmaceutical company. It focuses on discovering, developing, and commercialising prescription medicines. The company operates primarily in four therapy areas. These include Oncology, Cardiovascular, Renal & Metabolism, and Respiratory. AstraZeneca is dedicated to transforming the future of healthcare. By unlocking the power of science, the company aims to deliver life-changing medicines to patients worldwide.

AstraZeneca falls under the pharmaceutical sector, specifically within the biopharmaceutical sub-sector. The company has been in business since 1999, following the merger of Astra AB of Sweden and Zeneca Group PLC of the UK. This merger created one of the largest pharmaceutical companies in the world, with a strong focus on research and development.

The headquarters of AstraZeneca Pharma Ltd is located in Bengaluru, Karnataka. The company is a subsidiary of AstraZeneca PLC, UK, and operates under the guidance of its global leadership team. The leading promoters of the company include AstraZeneca Pharmaceuticals AB with a 75.00% stake in the company. A team of professional managerial promoters manages the operations of the company-

Narayan K Seshadri
Sanjeev Kumar Panchal
Bhavana Agrawal
Sylvia Lorena Varela Ramon
Hooi Bien Chuah

The company is known for its innovative medicines. These medicines include treatments for cancer, cardiovascular diseases, diabetes, and respiratory diseases. It also develops therapies for rare diseases. Some of its well-known products include Tagrisso, Symbicort, and Farxiga.

While it is a significant player in the pharmaceutical industry, it is not currently the most prominent company. Additionally, it does not lead to market capitalization. However, it is highly respected for its contributions to medical research. The company is also dedicated to improving patient outcomes.

The registered office of AstraZeneca Pharma India Limited is located in Block N1, Bengaluru. Additionally, the registrar's office is situated in Ramana Residency, Bengaluru. It is a leading biopharmaceutical company with a strong focus on research and development. AstraZeneca continues to innovate and deliver life-changing medicines to patients around the world.

Vision of AstraZeneca Pharma India Limited

AstraZeneca Pharma Ltd sees a future where medicines that alter lives change the existence of patients throughout the world. The company's vision is based on its dedication to scientific innovation and long-lasting health care solutions. This vision propels all parts of AstraZeneca’s operations. It influences areas ranging from research and development to community engagement.

The main purpose of AstraZeneca is to advance in the field of science for providing inventive medicines. The firm puts a lot into research and development work. They center their attention on areas where medical demands are not yet fully met. This encompasses the study of cancer and respiratory disorders. Its goal is to explore and advance therapies that treat symptoms as well as target the root causes of illnesses.

Sustainability is a key component of AstraZeneca’s vision. The company is committed to reducing its environmental footprint and promoting sustainable healthcare practices. AstraZeneca has set ambitious targets to achieve zero carbon emissions from its global operations by 2025. The company also reduces waste and promotes biodiversity. These efforts reflect AstraZeneca’s belief that a healthy planet is essential for healthy people.

Innovation extends beyond medicine at AstraZeneca. The company leverages digital technologies to enhance patient care and streamline operations. Digital health solutions, such as remote monitoring and telemedicine, enable patients to receive care from the comfort of their homes.

AstraZeneca’s vision includes a strong commitment to ethical business practices. The company upholds high integrity and accountability standards in all its operations. AstraZeneca ensures that its medicines are safe and accessible to those who need them. The company also advocates for policies supporting innovation and patient healthcare access. This ethical approach builds trust with patients and stakeholders.

Community engagement is another important aspect of AstraZeneca’s vision. The company actively participates in initiatives promoting health and well-being in its communities. AstraZeneca supports educational programs and charitable activities. These efforts aim to improve public health and address social determinants of health. AstraZeneca’s community engagement reflects its commitment to making a positive impact beyond the healthcare sector.

AstraZeneca’s vision is also about fostering a culture of diversity and inclusion. The company believes that diverse perspectives drive innovation and improve decision-making. AstraZeneca promotes an inclusive workplace where employees feel valued and empowered. The company provides opportunities for professional development and encourages collaboration across different functions and geographies. This inclusive culture is essential for achieving AstraZeneca’s mission of delivering life-changing medicines.

The vision of AstraZeneca extends to its partnerships and collaborations. The company works with academic institutions and pharmaceutical companies to advance medical science. These partnerships enable AstraZeneca to leverage external expertise and resources, accelerating the development of new treatments. Collaborative efforts also facilitate knowledge sharing and innovation, benefiting the broader healthcare community.

AstraZeneca’s vision is future-focused, anticipating the evolving needs of patients and healthcare systems. The company is committed to continuous improvement and adaptation in response to emerging health challenges. AstraZeneca invests in cutting-edge research, explores new therapeutic areas, and embraces innovative technologies. This forward-thinking approach ensures that AstraZeneca remains at the forefront of medical advancements.